• PDF: Delivered by email usually within 12 to 48 UK business hours.

Pharmaceutical Pricing and Reimbursement in Europe
Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies

  • Publication Date:November 2011
  • Publisher:GBI Research
  • Product Type: Report
  • Pages:68

Pharmaceutical Pricing and Reimbursement in Europe Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies

Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies". It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in 12 European nations with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes the major changes in the pharmaceuticals related pricing and reimbursement in these European nations in the recent past and their impact in the near future. The countries analyzed in the report are the top five countries of Europe, Eastern European countries such as Czech Republic, Poland, Romania and Hungary as well as Scandinavian countries such as Norway, Finland and Denmark.

GBI Research's analysis describes healthcare across the 12 European nations, which is largely publicly financed and is provided by health insurance systems; hence, the European governments play a key role in providing healthcare for their citizens. Health is of high priority for Europe's citizens and pharmaceutical costs are the third most important component in the member states' healthcare budgets. Currently, the governments of the member countries face substantially rising costs for the provision of health care (average costs are rising at a faster rate than GDP) due to over-prescription of drugs, their irrational usage, and other key factors such as Europe's ageing population and increasing cost of new medical technologies. Consumer preference for branded drugs to generic drugs in cases where the patent for the drug has expired is also one of the reasons for increasing healthcare costs. Austerity packages announced by the countries are incorporating demand side and supply side policies to reduce the fiscal burden of which healthcare costs command a major proportion. The governmental demand side policies include measures that affect the reimbursements of drugs such as positive and negative lists, cost sharing, reference pricing, risk-sharing contracts, tenders, pay-back arrangements and other provisions aimed at a more rational use of pharmaceutical products and making demand more price sensitive. The most applied supply policy is price regulation which includes price control and price negotiation. The specific features of individual policies vary significantly across the member states. Single pricing mechanism is still an issue in the Europe.

Scope

  • Detailed study of the healthcare systems and roles of the key players in the respective pharmaceutical systems of top five countries of Europe - the UK, France, Germany, Italy and Spain; Eastern European countries of Czech Republic, Poland, Hungary, and Romania; and Scandinavian countries of Norway, Denmark and Finland.
  • Analysis of the major pricing and reimbursement mechanisms in each country.
  • Key trends that follow from the recent changes brought about in the pricing and reimbursement mechanism.
  • Build an understanding of the possible major challenges brought about by the enactment of changes in the pricing and reimbursement scene in the countries covered.

Reasons to buy

  • Build understanding of the pharmaceuticals related key pricing and reimbursement mechanisms in the key markets of Europe.
  • Optimize your investment through identification and understanding of the changes in the pharmaceuticals regulatory mechanism in the economies.
  • Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in pricing and reimbursement scene for the countries covered.
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Pricing and Reimbursement in Europe - Introduction
    • 2.1 GBI Research Report Guidance
  • 3 Pricing and Reimbursement in Europe - Overview
    • 3.1 Healthcare Expenditure Highly Correlated with GDP
    • 3.2 Relation between Pharmaceutical Expenditure and GDP
    • 3.3 Overview of Pharmaceutical Regulations in Europe
    • 3.3.1 Negotiations
    • 3.3.2 International Price Referencing
    • 3.3.3 Internal Reference Pricing
    • 3.3.4 Tendering
    • 3.3.5 Price Capping of Generic Pharmaceuticals
    • 3.3.6 Use of Positive and Negative Formulary
    • 3.3.7 Value Based Pricing and Risk-Sharing Models
    • 3.3.8 Increased Focus on Evidence-based Medicine and Health Technology Assessment (HTA)
    • 3.3.9 Role of Pharmacoeconomics in Pricing and Reimbursement
    • 3.3.10 EU Single Pricing - Still an Unresolved Issue
    • 3.4 Recent Major Changes in Pricing and Reimbursement of Drugs in Europe
    • 3.4.1 The UK to Adopt VBP Replacing PPRS from 2014 despite Concerns of Companies and Experts Alike
    • 3.4.2 Major Challenge Regarding VBP Adoption in the UK
    • 3.4.3 France Decreases Reimbursement for Drugs with Moderate Clinical Benefits Along With Overall Price Cuts
    • 3.4.4 Benefit Assessment Led Price Negotiation, Price Freeze and Mandatory Discounts Key Features Of German P&R Changes
    • 3.4.5 Italian P&R Scene Dominated By Price Cuts and Changes in Reference Price Level
    • 3.4.6 Main Austerity Measures in Spain Include 7.5% Rebate for In-Patent Drugs and Price Cuts for Generics
    • 3.4.7 Renewed P&R Cut Of 7% in Czech Republic and Proposed Changes in VAT for 2012 And 2013
    • 3.4.8 Expenditure on Reimbursement of Medicines Fixed At 17% of the NHF in Poland
    • 3.4.9 Levy on Sale of Reimbursed Drugs in Hungary to Go Up To 20%; Payment-By-Result another Major Move
  • 4 Pricing and Reimbursement in Europe - The Top Five Countries of Europe
    • 4.1 The UK
    • 4.1.1 Healthcare System in the UK
    • 4.1.2 Healthcare expenditure - Other Developed Countries More Prominent Healthcare Spenders
    • 4.1.3 Pricing and Reimbursement Process in the UK
    • 4.1.4 Key Trends
    • 4.1.5 Major Challenges
    • 4.2 France
    • 4.2.1 Healthcare System in France
    • 4.2.2 Pricing and Reimbursement Process in France
    • 4.2.3 Key Trends
    • 4.2.4 Major Challenges
    • 4.3 Germany
    • 4.3.1 Healthcare System in Germany
    • 4.3.2 Pricing and Reimbursement Process in Germany
    • 4.3.3 Key Trends
    • 4.3.4 Major Challenges
    • 4.4 Italy
    • 4.4.1 Healthcare System in Italy
    • 4.4.2 Pricing and Reimbursement Process in Italy
    • 4.4.3 Key Trends
    • 4.4.4 Major Challenges
    • 4.5 Spain
    • 4.5.1 Healthcare System in Spain
    • 4.5.2 Pricing and Reimbursement Process in Spain
    • 4.5.3 Key Trends
    • 4.5.4 Major Challenges
  • 5 Pricing and Reimbursement in Europe - Eastern Europe
    • 5.1 Czech Republic
    • 5.1.1 Healthcare System in Czech Republic
    • 5.1.2 Pricing and Reimbursement Process in the Czech Republic
    • 5.1.3 Key Trends
    • 5.1.4 Major Challenges
    • 5.2 Poland
    • 5.2.1 Healthcare System in Poland
    • 5.2.2 Pricing and Reimbursement Process in Poland
    • 5.2.3 Key Trends
    • 5.2.4 Major Challenges
    • 5.3 Romania
    • 5.3.1 Pricing and Reimbursement Process in Romania
    • 5.3.2 Key Trends
    • 5.3.3 Major Challenges
    • 5.4 Hungary
    • 5.4.1 Healthcare System in Hungary
    • 5.4.2 Pricing and Reimbursement Process in Hungary
    • 5.4.3 Key Trends
    • 5.4.4 Major Challenges
  • 6 Pricing and Reimbursement in Europe - Scandinavia
    • 6.1 Norway
    • 6.2 Finland
    • 6.3 Denmark
  • 7 Pricing and Reimbursement in Europe - Appendix
    • 7.1 Market Definitions
    • 7.2 Abbreviations
    • 7.3 Research Methodology
    • 7.3.1 Healthcare System
    • 7.3.2 Pricing and Reimbursement Process
    • 7.3.3 Key Trends
    • 7.3.4 Major Challenges
    • 7.4 Contact Us
    • 7.5 Disclaimer
    • 7.6 Sources
  • 1.1 List of Tables
    • Table 1: Pricing and Reimbursement in Europe, Supply-Side Pharmaceutical Regulations
    • Table 2: Pricing and Reimbursement in Europe, Demand-Side Pharmaceutical Regulations
    • Table 3: Pricing and Reimbursement in Europe, Regulatory Mechanisms in Top Five Countries of Europe
    • Table 4: Pricing and Reimbursement in Europe, the UK, General Price Changes (%), 2009-2013
    • Table 5: Pricing and Reimbursement in Europe, France, Types of Treatment and their Reimbursement levels
    • Table 6: Pricing and Reimbursement in Europe, France, Social Security Deficit, €bn and $bn, 2009-2011
    • Table 7: Pricing and Reimbursement in Europe, France, National Target for Expenditure in Public Healthcare/ ONDAM, €bn and $bn, 2010-2011
    • Table 8: Pricing and Reimbursement in Europe, List of Innovative Drugs for Regions, AIFA, 2010
    • Table 9: Pricing and Reimbursement in Europe, Regulatory Mechanisms in Eastern Europe
    • Table 10: Pricing and Reimbursement in Europe, Regulatory Mechanisms in the Scandinavian Countries
  • 1.2 List of Figures
    • Figure 1: Pricing and Reimbursement in Europe, Estimated Costs Paid by the Patient and Health Insurance System in the Total Reimbursed Pharmacy Market Value at Retail Prices (%), 2008
    • Figure 2: Pricing and Reimbursement in Europe, Healthy Life Years At 65 For Males And Females, 2009
    • Figure 3: Pricing and Reimbursement in Europe, Health expenditure per capita With Respect To GDP per capita, $PPP, 2009
    • Figure 4: Healthcare Expenditure in Europe and the US, Healthcare Expenditure as % of GDP, 1960-2008
    • Figure 5: Pricing and Reimbursement in Europe, Pharmaceutical Expenditure Per Capita And GDP Per Capita ($PPP), 2009
    • Figure 6: Pricing and Reimbursement in Europe, Value Based Pricing - Concept and Process
    • Figure 7: Pricing and Reimbursement in Europe, ISPOR 33 Guidelines for Pharmacoeconomics Assessment
    • Figure 8: Pricing and Reimbursement in Europe, Healthcare expenditure % of GDP, 2008
    • Figure 9: Pricing and Reimbursement in Europe, the UK, NHS expenditure on medicines ($bn) Vs NHS Medicines Cost per capita ($), 2000-2009
    • Figure 10: Pricing and Reimbursement in Europe, European Counties, the US, Japan, Total Healthcare Expenditure vs Out-of-Pocket Expenditure in European Countries, 2009
    • Figure 11: Pricing and Reimbursement in Europe, Pharmaceutical Expenditure Per Capita Among the Highest in France, $PPP, 2007-2008
    • Figure 12: Pricing and Reimbursement in Europe, LFSS 2011
    • Figure 13: Pricing and Reimbursement in Europe, Germany, Healthcare Expenditure, $ per inhabitant, 2008
    • Figure 14: Pricing and Reimbursement in Europe, Germany, Cost Containment Measures, 1980-2011
    • Figure 15: Pricing and Reimbursement in Europe, Germany, Structural Reforms by AMNOG, 2011
    • Figure 16: Pricing and Reimbursement in Europe, Romania, Key Aspects of New Pharmaceutical Regulations
+44 20 8816 8548

Ask a question about Pharmaceutical Pricing and Reimbursement in Europe

Enter the characters you see in the picture below
Captcha